Cartesian Therapeutics to Participate in Upcoming Investor Conferences
Rhea-AI Summary
Cartesian Therapeutics (NASDAQ: RNAC) said management will participate in investor conferences in March and April 2026, including a presentation at the 46th Annual TD Cowen Health Care Conference and fireside chats at Leerink and Needham.
Live webcasts and archived replays will be accessible in the Events section of the company website for a limited time.
Positive
- None.
Negative
- None.
News Market Reaction – RNAC
On the day this news was published, RNAC gained 0.72%, reflecting a mild positive market reaction. Argus tracked a peak move of +4.4% during that session. Our momentum scanner triggered 7 alerts that day, indicating moderate trading interest and price volatility. This price movement added approximately $1M to the company's valuation, bringing the market cap to $201.53M at that time. Trading volume was elevated at 2.3x the daily average, suggesting notable buying interest.
Data tracked by StockTitan Argus on the day of publication.
FREDERICK, Md., Feb. 23, 2026 (GLOBE NEWSWIRE) -- Cartesian Therapeutics, Inc. (NASDAQ: RNAC) (the “Company”), a clinical-stage biotechnology company pioneering cell therapy for autoimmune diseases, today announced that its management expects to participate in the following investor conferences in March and April:
- A presentation at the 46th Annual TD Cowen Health Care Conference at 11:50 a.m. ET Monday, March 2, 2026
- A fireside chat at Leerink’s Global Healthcare Conference at 10:00 a.m. ET on Monday, March 9, 2026
- A fireside chat at the 25th Annual Needham Virtual Healthcare Conference at 9:30 a.m. ET on Monday, April 13, 2026
Live webcasts of the fireside chats and presentation are expected to be accessible in the Events section of the Company’s website at www.cartesiantherapeutics.com, where an archived replay of the events will also be available for a limited time.
About Cartesian Therapeutics
Cartesian Therapeutics is a clinical-stage company pioneering cell therapy for the treatment of autoimmune diseases. The Company’s lead asset, Descartes-08, is a CAR-T in Phase 3 clinical development for patients with generalized myasthenia gravis with plans to initiate a Phase 2 trial in myositis. For more information, please visit www.cartesiantherapeutics.com or follow the Company on LinkedIn or X.
Investor Contact
Megan LeDuc
Associate Director, Investor Relations
megan.leduc@cartesiantx.com
Media Contact
David Rosen
Argot Partners
david.rosen@argotpartners.com
FAQ
When will Cartesian Therapeutics (RNAC) present at the TD Cowen Health Care Conference in 2026?
How can investors watch Cartesian Therapeutics (RNAC) fireside chats in March and April 2026?
What time is the Cartesian Therapeutics (RNAC) fireside chat at Leerink’s Global Healthcare Conference?
When is Cartesian Therapeutics (RNAC) scheduled to speak at the Needham Virtual Healthcare Conference?
Where will archived replays of Cartesian Therapeutics (RNAC) conference presentations be available?
